Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9956289 | SANTEN | Emulsion compositions containing quaternary ammonium compounds |
Jan, 2026
(1 year, 9 months from now) | |
US8524779 | SANTEN | Emulsion compositions containing quaternary ammonium compounds |
Jan, 2026
(1 year, 9 months from now) | |
US9220694 | SANTEN | Emulsion compositions containing cetalkonium chloride |
Jan, 2026
(1 year, 9 months from now) | |
US7973081 | SANTEN | Emulsion compositions containing quaternary ammonium compounds |
Jan, 2026
(1 year, 9 months from now) | |
US11612658 | SANTEN | Oil-in-water emulsions comprising cetalkonium chloride and methods of making and using the same |
Jan, 2026
(1 year, 9 months from now) | |
US8298568 | SANTEN | Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential |
Nov, 2027
(3 years from now) | |
US9132071 | SANTEN | Compositions containing quaternary ammonium compounds |
Jun, 2029
(5 years from now) |
Verkazia is owned by Santen.
Verkazia contains Cyclosporine.
Verkazia has a total of 7 drug patents out of which 0 drug patents have expired.
Verkazia was authorised for market use on 23 June, 2021.
Verkazia is available in emulsion;ophthalmic dosage forms.
Verkazia can be used as for the treatment of vernal keratoconjunctivitis in children and adults.
The generics of Verkazia are possible to be released after 02 June, 2029.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Jun 23, 2028 |
New Product (NP) | Jun 23, 2024 |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 23 June, 2021
Treatment: For the treatment of vernal keratoconjunctivitis in children and adults
Dosage: EMULSION;OPHTHALMIC